TABLE 1.
Clinical population characteristics for NSCLC-MSK and pan-cancer-VHIO cohort
| Cohort | NSCLC-MSK | pan-cancer-VHIO |
|---|---|---|
| N | 233 | 108 (106 treated with immunotherapy) |
| Age, median (range) | 68 (30–93) | 57 (29–77) |
| Sex | ||
| Male | 102 | 57 |
| Female | 131 | 51 |
| Treatment | ||
| Anti-PDL1 | N/A | 35 |
| Anti-PD1 | N/A | 13 |
| Anti-PD1 + other ICIs | N/A | 30 |
| Anti-PDL1 + other ICIs | N/A | 8 |
| Other ICIs | N/A | 14 |
| Anti-PD1 + chemotherapy | N/A | 4 |
| Other combinations | N/A | 4 |
| Tumor type | ||
| Lung | 233 | 27 |
| Gastrointestinal (including gastric, colon, pancreas) | 22 | |
| Melanoma | 10 | |
| Gynecologic (including ovarian, uterine, and endometrial) | 9 | |
| Breast | 8 | |
| Urinary | 6 | |
| Head and neck | 8 | |
| Hepatobiliary | 4 | |
| Sarcoma | 3 | |
| Other | 9 | |
| Biopsy location | ||
| Primary | 105 | 69 |
| Metastatic | 128 | 39 |
| PD-L1 expression | ||
| TPS < 1% | 73 | 59 |
| TPS ≥ 1% | 163 | 49 |
| Best response | ||
| CR/PR | 70 | 16 |
| SD/PD | 154 | 90 |
| PFS in months [median (95% CI)] | 3.2 (2.6–4.7) | 2.73 (1.84–3.98) |
Abbreviations: CI, confidence interval; CR, complete response; ICI, immune checkpoint inhibitors; N/A, not available; PD, progressive disease; PR, partial response; SD, stable disease; TPS, tumor proportion score.